Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Category for old articles
The week of November 24-29 closed with continued volatility as investors digested stretched AI valuations, mixed macro signals, and elevated geopolitical tensions. Major indexes ended modestly lower: S&P 500 [finance:S&P 500] -1.9%, Nasdaq [finance:Nasdaq Composite] -2.7%, Dow [finance:Dow Jones Industrial Average] -1.9%.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company specializing in the development, manufacturing, and commercialization of rapid PCR diagnostic tests. Core focus: affordable, rapid tuberculosis (TB) detection tests for global markets (MENA, Africa, Asia). Company historically revenue-focused but currently in severe financial distress with strategic pivots toward AI and international partnerships.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of pharmaceutical products using its proprietary gene science approach. The company operates in two segments: Product (INPEFA® commercialization) and Licensing (Novo Nordisk partnership for LX9851 obesity program).
OneMedNet Corporation (NASDAQ: ONMD) is a healthcare technology company specializing in curating and providing regulatory-grade Real-World Data (RWD) through its proprietary iRWD™ platform. The company connects life sciences organizations, medical device companies, and AI researchers with de-identified medical imaging, electronic health records, and clinical data from over 2,130 healthcare provider sites spanning 47+ million unique patient lives and 186+ million clinical exams.
Microbot Medical is a commercial-stage medical device company specializing in endovascular robotic systems. The company achieved a transformational milestone in September 2025 with FDA 510(k) clearance for its flagship LIBERTY® Endovascular Robotic System - the world's first FDA-cleared single-use, remotely operated robotic platform for peripheral endovascular procedures.
Verrica Pharmaceuticals [finance:Verrica Pharmaceuticals Inc.] (NASDAQ: VRCA) is a commercial-stage dermatology biopharmaceutical company focused on developing and commercializing innovative medical aesthetic solutions for skin conditions including molluscum contagiosum, basal cell carcinoma, and aesthetic dermatology indications. The company operates through a partnership model, leveraging strategic alliances with larger pharmaceutical companies (Torii Pharmaceutical [finance:Torii Pharmaceutical Co., Ltd.]) for commercialization and geographic expansion.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a clinical-stage dermatology-focused biopharmaceutical company developing innovative immunological therapies for inflammatory and immune-mediated skin diseases. The company transitioned from a commercial-stage company with FDA-approved products to a clinical-stage organization, strategically acquiring promising pipeline assets to build a competitive portfolio in atopic dermatitis and related indications.
Diagnostics + Therapeutics | Genetic Testing & Cancer Drug Development | Q3 2025 Report
Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biopharmaceutical company pioneering the development of masked tumor-activated immunotherapies
? Amarin Corporation (AMRN) – Company History & Analysis ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a company analysis and financial summary compiled from publicly available sources (SEC filings, press releases, clinical publications). It is NOT investment advice,…
What happened: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed Anavex of a negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its oral explanation on November 11, 2025.
NRx Pharmaceuticals (NRXP) | Investment Research Report ⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE: This document is a news digest and company profile compiled from publicly available sources (SEC filings, press releases, official company announcements). It is NOT investment advice, NOT…
Cue Biopharma (CUE) | Investment Research Report ?? English Version ? Cue Biopharma (CUE) Investment Research Report — Platform Play: Immuno-STAT T-Cell Modulators Update: November 26, 2025 ⚠️ GOING CONCERN WARNING ? STRATEGIC PIVOT TO AUTOIMMUNE NASDAQ: CUE | Price:…
KALA Bio was a clinical-stage biotech developing KPI-012, a mesenchymal stem cell secretome (MSC-S) therapy for Persistent Corneal Epithelial Defect (PCED), an orphan eye disease with ~100,000 US patients and no FDA-approved treatments.
"Will PLRX have a merry Christmas?
Very speculative play .
ummit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical company focused on developing innovative oncology therapies. The primary pipeline is built around ivonescimab, a first-in-class bispecific antibody developed in partnership with Akeso Biopharma (China).
Scientific Comparison of Anti-Obesity Drug Efficacy 2025 – Complete Report Scientific Comparison of Anti-Obesity Drug Efficacy Semaglutide, Tirzepatide, Liraglutide, and Pemvidutide Complete Scientific Report – Updated: November 25, 2025 Table of Contents 1. Introduction 2. Mechanisms of Action and Pharmacological…
Symbotic surges +35% post-earnings; valuation tightens as growth investors price in upside
ADMA Biologics is a rare biotech company that combines clinical success with financial profitability. Unlike pre-revenue biotech plays, ADMA operates a functioning immunoglobulin (plasma-derived therapy) business generating $426.5M in FY2024 revenue (+65% YoY) with actual net income of $197.7M. The company is well-managed, debt-reducing, and positioned in a high-growth market ($53.5B global plasma therapy market projected by 2033).
FDA APPROVED BUT HIGH DILUTION RISK